Latest News and Press Releases

Targeting completion of enrollment in registrational cohort of DELTA-1 in 2022Presenting preclinical efficacy and safety data of CoStAR platform at ASCO 2022Cash runway into 2024 through key clinical...

- Initiated DELTA-1, a Phase 2 trial of ITIL-168 in advanced melanoma with registrational intent - Received orphan drug and fast-track designation from the U.S. FDA for lead pipeline candidate,...

DALLAS, March 02, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL,...

Patients enrolled and recruitment ongoing in Phase 2 trial of ITIL-168 in melanoma (DELTA-1)Fast Track Designation granted by FDA for ITIL-168 in metastatic melanomaCoStAR mechanism of action data...

DALLAS, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies...

DALLAS, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies...

DALLAS, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL,...

Main Study Cohort: Phase 2 clinical trial with registrational intent for patients with advanced melanoma Additional Cohorts: ITIL-168 clinical trial expanded during IND review process with two...

DALLAS, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL,...

- Presented compassionate use study in advanced melanoma demonstrating 67% of subjects achieved an objective response with 19% achieving a complete response - Received orphan drug designation from...